This site is intended for U.S. Healthcare Professionals only.



IBD GAPPS stands for Inflammatory Bowel Disease Global Assessment of Patient and Physician Unmet Needs Survey.

Dr David Rubin, Section Chief of Gastroenterology, Hepatology and Nutrition of the University of Chicago Medicine, explains the rationale for IBD GAPPS and highlights some key findings.

One of the largest surveys of its kind, this global initiative was created by Bristol Myers Squibb in 2019 to highlight the impact of the evolving inflammatory bowel disease (IBD) treatment landscape on patients with ulcerative colitis and Crohn’s disease and their healthcare providers (HCPs). The survey explored perceptions about symptoms and treatment efficacy, management of disease and treatment patterns, treatment satisfaction and goals, burden of disease/care, and HCP/patient communication. The survey was completed by more than 2,300 adult patients with IBD and over 650 gastroenterologists from:

  • The United States
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • The United Kingdom

IBD GAPPS was validated through the combined efforts of a multinational Steering Committee of 9 IBD experts, advocacy partners, and patients.

The Importance of IBD GAPPS

The initiative has revealed valuable insights into patient and prescriber perceptions of unmet needs in IBD — such as the need for improved communication between patients and physicians.


Steroid Use

The majority of survey respondents reported concern with varying durations of steroid usage

Disease Remission

A majority of patient and physician respondents have different definitions of remission

Symptom Burden

Patients reported a strong impact of IBD on their well-being

Download and Share the IBD GAPPS Findings


See What the Experts Are Saying About IBD GAPPS Findings

Click to Discover >

1 Rubin D, et al. Definition of remission in inflammatory bowel disease: assessment of patient and physician perspectives. Inflamm Bowel Dis. 2020;26(S1):S77.

2 Afzali A, et al. Patient and physician perspectives on the management of inflammatory bowel disease: disease remission and durability of treatment. J Crohn’s Colitis. 2020;14(S1):S424.

3 Afzali A, et al. Patient and physician perspectives on the management of inflammatory bowel disease: role of steroids in the context of biologic therapy. J Crohn’s Colitis. 2020;14(S1):S366-7.

4 Rubin DT, et al. International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey. Inflamm Bowel Dis. 2021. doi: 10.1093/ibd/izab006.